Gan & Lee Pharmaceuticals (SHA:603087) dosed its first patient for its phase 1 clinical trial of its self-developed GLR2053 drug, according to a Tuesday filing with the Shanghai bourse.
The drug is indicated for atopic dermatitis and is designed to degrade the STAT6 target protein.
Research and development costs for the drug have reached 71.6 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments